NYSE-listed IonQ, which builds trapped-ion quantum computers, will partner with Toronto-based Centre for Commercialization of Regenerative Medicine (CCRM) and CCRM Nordic to develop next-generation therapeutic development using hybrid quantum and quantum-AI technologies. This collaboration will initially focus on areas including bioprocess optimization, disease-modeling workflows, and quantum enhanced simulation to support the design and manufacturing of advanced therapies.
As part of the partnership, IonQ will invest an undisclosed amount into creating a joint DeepTech Bio Lab™ to explore the possibilities of using quantum computing in life-science applications. IonQ will also leverage CCRM’s research centres and incubators in Canada and Sweden – where both companies have a presence.
This announcement builds upon IonQ’s collaboration with AstraZeneca to establish a new quantum application development center at GoCo Health Innovation City in Gothenburg, where CCRM Nordic is also located.
